Cargando…

Prognostic significance of galectin‐3 expression in patients with resected NSCLC treated with platinum‐based adjuvant chemotherapy

BACKGROUND: Galectin‐3 (GAL3), a protein encoded by the LGALS3 gene, plays diverse roles in cancer initiation, progression, and drug resistance. Accordingly, high GAL3 expression in tumor cells is associated with poor prognosis in non‐small cell lung cancer (NSCLC). However, the prognostic impact of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kusuhara, Seiichiro, Igawa, Satoshi, Ichinoe, Masaaki, Nagashio, Ryo, Kuchitsu, Yuki, Hiyoshi, Yasuhiro, Shiomi, Kazu, Murakumo, Yoshiki, Saegusa, Makoto, Satoh, Yukitoshi, Sato, Yuichi, Naoki, Katsuhiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107024/ https://www.ncbi.nlm.nih.gov/pubmed/33793071 http://dx.doi.org/10.1111/1759-7714.13945

Ejemplares similares

Prognostic significance of nestin expression in patients with resected non-small cell lung cancer treated with platinum-based adjuvant chemotherapy; relationship between nestin expression and epithelial to mesenchymal transition related markers
por: Ryuge, Shinichiro, et al.
Publicado: (2017)

Prognostic significance of IMMT expression in surgically‐resected lung adenocarcinoma
por: Hiyoshi, Yasuhiro, et al.
Publicado: (2019)

S100A16, a promising candidate as a prognostic marker for platinum-based adjuvant chemotherapy in resected lung adenocarcinoma
por: Katono, Ken, et al.
Publicado: (2017)

REV7 in Cancer Biology and Management
por: Murakumo, Yoshiki, et al.
Publicado: (2023)

Examination of the effectiveness of local therapy for oligo‐recurrence of EGFR‐mutated NSCLC
por: Sonoda, Dai, et al.
Publicado: (2023)

Efficacy and risk of cytotoxic chemotherapy in extensive disease-small cell lung cancer patients with interstitial pneumonia
por: Shirasawa, Masayuki, et al.
Publicado: (2019)

Prognostic values of L-type amino acid transporter 1 and CD98hc expression in breast cancer
por: Ichinoe, Masaaki, et al.
Publicado: (2021)

Abnormal branching of the left lingular pulmonary artery diagnosed by three-dimensional computed tomographic angiography in a patient with lung cancer: a case report
por: Sonoda, Dai, et al.
Publicado: (2016)

Effect of adjuvant chemotherapy after pulmonary metastasectomy on the prognosis of colorectal cancer
por: Shiomi, Kazu, et al.
Publicado: (2017)

Diagnostic and Prognostic Significances of MUC5B and TTF-1 Expressions in Resected Non-Small Cell Lung Cancer
por: Nagashio, Ryo, et al.
Publicado: (2015)

High expression of L-type amino acid transporter 1 as a prognostic marker in bile duct adenocarcinomas
por: Yanagisawa, Nobuyuki, et al.
Publicado: (2014)

Prognostic Significance of MYH9 Expression in Resected Non-Small Cell Lung Cancer
por: Katono, Ken, et al.
Publicado: (2015)

Spontaneous non-traumatic mediastinal hematoma associated with oral anticoagulant therapy: A case report and literature review
por: Mikubo, Masashi, et al.
Publicado: (2017)

Prognostic implications of prostaglandin E-major urinary metabolite in resected non-small-cell lung cancer
por: Mikubo, Masashi, et al.
Publicado: (2023)

Comparison between quantitative computed tomography, scintigraphy, and anatomical methods for prediction of postoperative FEV(1) and DLCO: effects of chronic obstructive pulmonary disease status and resected lobes
por: Yokoba, Masanori, et al.
Publicado: (2020)

CAXII Is a Sero-Diagnostic Marker for Lung Cancer
por: Kobayashi, Makoto, et al.
Publicado: (2012)

Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non‐small cell lung cancer harboring an EGFR mutation: A prospective observational study
por: Ono, Taihei, et al.
Publicado: (2019)

Impact of EGFR genotype on the efficacy of osimertinib in EGFR tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study
por: Igawa, Satoshi, et al.
Publicado: (2019)

Factors associated with lymph node metastasis upstage after resection for patients with micropapillary lung adenocarcinoma
por: Matsushima, Keigo, et al.
Publicado: (2021)

Prognostic differences between oligometastatic and polymetastatic extensive disease-small cell lung cancer
por: Shirasawa, Masayuki, et al.
Publicado: (2019)

Prognostic significance of the 8th edition of the TNM classification for patients with extensive disease small cell lung cancer
por: Shirasawa, Masayuki, et al.
Publicado: (2018)

Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non‐small cell lung cancer prior to the approval of durvalumab
por: Fukui, Tomoya, et al.
Publicado: (2020)

Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib
por: Zhang, Shannon S, et al.
Publicado: (2022)

Deconstructing ADAURA. It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIA) EGFR-mutant NSCLC
por: Brazel, Danielle, et al.
Publicado: (2022)

Multiple primary pulmonary meningiomas: 20-year follow-up findings for a first reported case confirming a benign biological nature
por: Satoh, Yukitoshi, et al.
Publicado: (2017)

Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC
por: Yi, Chengxiang, et al.
Publicado: (2019)

Influence of Programmed Death Ligand-1-Gene Polymorphism rs822336 on the Prognosis and Safety of Postoperative Patients with NSCLC Who Received Platinum-Based Adjuvant Chemotherapy
por: Zhao, Ming, et al.
Publicado: (2020)

Update on adjuvant therapy in completely resected NSCLC patients
por: Lim, Jeong Uk, et al.
Publicado: (2021)

Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC
por: Walia, Anushka, et al.
Publicado: (2023)

A Prospective Observational Study of Osimertinib for Chemo-Naive Elderly Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer
por: Igawa, Satoshi, et al.
Publicado: (2021)

The role of expression and polymorphism of the BAG-1 gene in response to platinum-based chemotherapeutics in NSCLC
por: WANG, YA-DI, et al.
Publicado: (2011)

Sequential Whole Exome Sequencing Reveals Somatic Mutations Associated with Platinum Response in NSCLC
por: Guo, Ao-Xiang, et al.
Publicado: (2020)

Clinical staging of NSCLC: current evidence and implications for adjuvant chemotherapy
por: Heineman, David J., et al.
Publicado: (2017)

Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma
por: Zhai, Xiaoyu, et al.
Publicado: (2017)

Interstitial pneumonia following administration of pegfilgrastim during carboplatin and etoposide chemotherapy for small-cell lung cancer
por: Shirasawa, Masayuki, et al.
Publicado: (2016)

Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy
por: Shimizu, Katsuhiko, et al.
Publicado: (2015)

Study on the Predictive Value of P53 Protein Expression in Brain Metastasis in NSCLC and the Mechanism of miR-424 Reversing Platinum Resistance in NSCLC
por: Deng, Yan, et al.
Publicado: (2022)

Polymorphisms of CCNB1 Associated With the Clinical Outcomes of Platinum-Based Chemotherapy in Chinese NSCLC Patients
por: Liu, Di, et al.
Publicado: (2017)

Pharmacogenomics of platinum-based chemotherapy response in NSCLC: a genotyping study and a pooled analysis
por: Chen, Juan, et al.
Publicado: (2016)

Retracted: Study on the Predictive Value of P53 Protein Expression in Brain Metastasis in NSCLC and the Mechanism of miR-424 Reversing Platinum Resistance in NSCLC
por: Imaging, Contrast Media & Molecular
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ughq9v12mgaffbl46ml03d7np7